ERBB2 and breast cancer: Although molecular targeted therapy such as trastuzumab, pertuzumab, lapatinib has achieved good curative effects on human epidermal growth factor receptor-2 (HER-2)-positive BC, there is limited efficacious treatment options for triple negative BC (TNBC) (2).